Who would sell today given 510k Submission and Wedbush Investor Conference Next Week?
Possibly a Hedge Fund such as Broadfin exiting into strength and liquidity since they were in at $.70 - 1.00. Look forward to seeing updated SEC 13G/A filings for Q2.
1)What do you think is the probability of $2.00+ by 12/31/13?
2)A buy-out offer from either Covidien, J&J by end of year?
3)A 510k approval of the Microcutter-Stapler by 12/31/13?
For the scenario builders out there, what is the likelihood of only one company dominating the Stapler-Cutter market in 5 years. I.e. of the two existing players Covidien and J&J letting the other bid for the 510k approved stapler-cutter or both letting Cardica enter and dominate the market (a monopoly) in 5 years?
Depending on your answers, consider the topic...."Just Plain Stupid to be selling today!"
1. $2.00 by 12/31/13 100%
2. Buyout by end of year 10%
3. FDA Approval - 50% It was a surprise that a trial was required in the first place given autosuture already on market. FDA has been better about responding to small company's on venture money.
The tea leave that will be exposed soon is CRDC's plan for US commercial marketing plan. Once they submit, they have to begin developing a plan that can be ready to implement upon the FDA approval. So will they begin hiring a team, us a US Co-Marketer such as AMC or ISRG or do nothing which indicates selling company. It will all begin to start moving quickly upon the submission.